Tag Archives: Fast Track Status

May, 2017

3 May
Altor BioScience’s Investigational Bladder Cancer Drug Granted Fast Track Status from the FDA

MIRAMAR, Fla.–(BUSINESS WIRE)–Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for …
Share

14 March
GW Pharma’s Cannabis Drug Succeeds in Late-Stage Study in Patients with Dravet Syndrome

London, UK; 14 March 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine …
Share